WO2002004514A3 - Compositions and methods for the therapy and diagnosis of lung cancer - Google Patents

Compositions and methods for the therapy and diagnosis of lung cancer Download PDF

Info

Publication number
WO2002004514A3
WO2002004514A3 PCT/US2001/022058 US0122058W WO0204514A3 WO 2002004514 A3 WO2002004514 A3 WO 2002004514A3 US 0122058 W US0122058 W US 0122058W WO 0204514 A3 WO0204514 A3 WO 0204514A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
lung cancer
therapy
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/022058
Other languages
French (fr)
Other versions
WO2002004514A8 (en
WO2002004514A2 (en
Inventor
Tongtong Wang
Yoshihiro Watanabe
Robert A Henderson
Jeffrey C Johnson
Marc W Retter
Margarita Durham
Darrick Carter
Gary Richard Fanger
Thomas S Vedvick
Chaitanya S Bangur
Andria Mcnabb
Aijun Wang
Neil Fanger
Ann Switzer
Patricia D Mcneill
Jonathan D Clapper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/614,124 external-priority patent/US6630574B1/en
Priority claimed from US09/651,563 external-priority patent/US6914132B1/en
Priority claimed from US09/658,824 external-priority patent/US6746846B1/en
Priority claimed from US09/671,325 external-priority patent/US6667154B1/en
Priority claimed from US09/702,705 external-priority patent/US6504010B1/en
Priority claimed from US09/736,457 external-priority patent/US6509448B2/en
Priority claimed from US09/849,626 external-priority patent/US20020197669A1/en
Priority to CA002415544A priority Critical patent/CA2415544A1/en
Priority to JP2002509377A priority patent/JP2004512824A/en
Priority to AU2002218770A priority patent/AU2002218770A1/en
Priority to EP01984164A priority patent/EP1343886A2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of WO2002004514A2 publication Critical patent/WO2002004514A2/en
Publication of WO2002004514A8 publication Critical patent/WO2002004514A8/en
Anticipated expiration legal-status Critical
Publication of WO2002004514A3 publication Critical patent/WO2002004514A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
PCT/US2001/022058 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer Ceased WO2002004514A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01984164A EP1343886A2 (en) 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer
AU2002218770A AU2002218770A1 (en) 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer
JP2002509377A JP2004512824A (en) 2000-07-11 2001-07-10 Compositions and methods for treatment and diagnosis of lung cancer
CA002415544A CA2415544A1 (en) 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US09/614,124 2000-07-11
US09/614,124 US6630574B1 (en) 1999-06-30 2000-07-11 Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563 2000-08-29
US09/651,563 US6914132B1 (en) 1999-06-30 2000-08-29 Compositions and methods for the therapy and diagnosis of lung cancer
US09/658,824 US6746846B1 (en) 1999-06-30 2000-09-08 Methods for diagnosing lung cancer
US09/658,824 2000-09-08
US09/671,325 2000-09-26
US09/671,325 US6667154B1 (en) 1999-06-30 2000-09-26 Compositions and methods for the therapy and diagnosis of lung cancer
US67741900A 2000-10-06 2000-10-06
US09/677,419 2000-10-06
US09/702,705 2000-10-30
US09/702,705 US6504010B1 (en) 1999-06-30 2000-10-30 Compositions and methods for the therapy and diagnosis of lung cancer
US09/736,457 2000-12-13
US09/736,457 US6509448B2 (en) 1999-06-30 2000-12-13 Compositions and methods for the therapy and diagnosis of lung cancer
US09/849,626 US20020197669A1 (en) 2000-12-13 2001-05-03 Compositions and methods for the therapy and diagnosis of lung cancer
US09/849,626 2001-05-03

Publications (3)

Publication Number Publication Date
WO2002004514A2 WO2002004514A2 (en) 2002-01-17
WO2002004514A8 WO2002004514A8 (en) 2002-12-27
WO2002004514A3 true WO2002004514A3 (en) 2003-06-19

Family

ID=27575493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022058 Ceased WO2002004514A2 (en) 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer

Country Status (6)

Country Link
EP (1) EP1343886A2 (en)
JP (1) JP2004512824A (en)
AR (1) AR031250A1 (en)
AU (1) AU2002218770A1 (en)
CA (1) CA2415544A1 (en)
WO (1) WO2002004514A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
EP1672070A3 (en) * 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166300A1 (en) * 2000-08-30 2003-09-04 Tang Y. Tom Growth-related inflammatory and immune response protein
ZA200204907B (en) 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
CN1681834A (en) * 2002-08-14 2005-10-12 株式会社Lg生命科学 Gene families associated with liver cancer
JP2006519582A (en) * 2002-09-26 2006-08-31 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of psoriasis
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US7449291B1 (en) * 2003-01-13 2008-11-11 University Of Washington Methods for identifying subjects susceptible to Charcot-Marie-Tooth neuropathy type 1C
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
AU2004224448A1 (en) * 2003-03-24 2004-10-07 Corixa Corporation Detection and monitoring of lung cancer
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
CN1898563B (en) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 Ways to Diagnose Breast Cancer
JP4428995B2 (en) 2003-12-03 2010-03-10 関東化学株式会社 Etching solution composition for metal film
WO2006131783A2 (en) * 2004-01-27 2006-12-14 Compugen Usa, Inc. Polynucleotides, polypeptides, and diagnosing lung cancer
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
ATE550661T1 (en) 2004-03-31 2012-04-15 Hiroyuki Aburatani CANCER DIAGNOSIS AND TREATMENT USING AN ANTI-ROBO1 ANTIBODY
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
EP1915622A2 (en) * 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP2010512786A (en) * 2006-12-21 2010-04-30 イントラダイム コーポレイション Inhibitory polynucleotide compositions and methods for treating cancer
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
CN101835892B (en) 2007-08-20 2013-11-06 肿瘤疗法科学股份有限公司 CDCA1 peptide and pharmaceutical agent comprising the same
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
CN102428102A (en) * 2009-05-22 2012-04-25 国立大学法人冈山大学 Peptides Inducing XAGE-1b Specific Immune Response and Their Utilization
WO2014010229A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
TW202023581A (en) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 Cdca1-derived peptide and vaccine containing same
CN114102955B (en) * 2020-08-31 2024-05-07 天津科技大学 Method for preparing foaming polylactic acid by adopting normal-temperature foaming technology

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038973A2 (en) * 1998-01-28 1999-08-05 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2000055375A1 (en) * 1999-03-17 2000-09-21 Alphagene, Inc. Secreted proteins and polynucleotides encoding them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10139800A (en) * 1996-11-15 1998-05-26 Santen Pharmaceut Co Ltd Agent for Sjogren's syndrome
MXPA02000192A (en) * 1999-06-30 2004-08-12 Corixa Corp Compositions and methods for the therapy and diagnosis of lung cancer.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038973A2 (en) * 1998-01-28 1999-08-05 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2000055375A1 (en) * 1999-03-17 2000-09-21 Alphagene, Inc. Secreted proteins and polynucleotides encoding them

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN S-L ET AL: "Isolation and characterizaton of a novel gene expressed in multiple cancers", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 12, no. 4, 15 February 1996 (1996-02-15), pages 741 - 751, XP002106655, ISSN: 0950-9232 *
DATABASE EMBL [online] 1 July 1997 (1997-07-01), "ab23f06.r1 Stratagene lung (#937210) Homo sapiens cDNA clone", XP002199797, Database accession no. AA488696 *
DATABASE EMBL [online] 5 March 1995 (1995-03-05), XP002199799, Database accession no. T63732.1 *
DATABASE EMBL [online] 7 June 2000 (2000-06-07), "Homo sapiens cDNA", XP002199798, Database accession no. AW950090 *
GÜRE ET AL: "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, 1 March 1998 (1998-03-01), pages 1034 - 1041, XP002103188, ISSN: 0008-5472 *
HILLIER L ET AL: "GENERATION AND ANALYSIS OF 280,000 HUMAN EXPRESSED SEQUENCE TAGS", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 6, 1996, pages 807 - 828, XP002942261, ISSN: 1088-9051 *
ZANGEMEISTER-WITTKE U ET AL: "REVIEW NOVEL APPROACHES TO THE TREATMENT OF SMALL-CELL LUNG CANCER", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, BASEL, CH, vol. 55, no. 12, September 1999 (1999-09-01), pages 1585 - 1598, XP000960960, ISSN: 1420-682X *

Also Published As

Publication number Publication date
CA2415544A1 (en) 2002-01-17
AR031250A1 (en) 2003-09-17
WO2002004514A8 (en) 2002-12-27
EP1343886A2 (en) 2003-09-17
JP2004512824A (en) 2004-04-30
AU2002218770A1 (en) 2002-01-21
WO2002004514A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002016413A3 (en) Cripto tumour polypeptide
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002014503A3 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2003086175A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 2415544

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001984164

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001984164

Country of ref document: EP